Publications Gastric, Abdominal and Colorectal Cancer

  • CORE 2
    FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with
     KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

    T. Brodowicz, T. E. Ciuleanu, D. Radosavljevic, E. Shacham-Shmueli, D. Vrbanec, S. Plate, Z. Mrsic-Krmpotic, M. Dank, G. Purkalne, D. Messinger, and C. C. Zielinski

    Ann Oncol (2013) 24 (7): 1769-1777 first published online April 4, 2013

  • Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.

    Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC.

    World J Gastroenterol. 2010 Jul 7;16(25):3133-43.

  • A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX-6 + Cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients with metastatic colorectal cancer.

    T. Ciuleanu, G. Kurteva, J. Ocvirk, S. Beslija, I. Koza, D. Papamichael, D. Vrbanec, T. Brodowicz, W. Scheithauer, C. Zielinski

    J. Clin. Oncol (supplement to 26) 2008: #4032

  • Gemcitabine plus Capecitabine versus Gemcitabine alone in advanced pancreatic cancer. A randomized phase III trial.

    Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E. Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W, Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group.

    Journal of Clinical Oncology, 2007,25: 2212-2217

  • Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial–SAKK 44/00-CECOG/PAN.1.3.001.

    Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group.

    J Clin. Oncol. 2008 Aug 1;26(22): 3695-701

  • Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophago-gastric cancer previously untreated with chemotherapy for advanced disease. Results of the CECOG-Study ESGAS.1.2.001.

    Hejna M, Raderer M, Zacherl J, Ba-Ssalamah A, Püspök A, Pluschnig U, Brodowicz T, Zielinski C.

    Anti-Cancer Drugs, 2008, 19:535-539

  • Consensus on the Medical Treatment of Colon Cancer

    Kornek G, Scheithauer W, Anghel R, Bodoky G, Ciardiello F, Ciuleanu T, Glynne-Jones R, Grünberger T, Koza I, Ocvirk J, Petruzelka L, Poston G, Ramadori G, Schmiegel W, Segaert S, Tabernero J, Zwierzina H, Zielinski C.

    Memo (2008) Vol.1: 79-90

For publications of the results of the Consensus Conferenences
see Consensus Statements »